- Home
- MDCX vs APRE Comparison
MDCX vs APRE Comparison
Compare MDCX & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | APRE |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 7.5M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MDCX | APRE |
|---|---|---|
| Price | $2.50 | $0.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $266.67 | $3.30 |
| AVG Volume (30 Days) | ★ 1.4M | 245.1K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.51 |
| 52 Week High | $4.69 | $1.49 |
Technical Indicators
Market Signals| Indicator | MDCX | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 32.93 |
| Support Level | $0.26 | N/A |
| Resistance Level | $4.69 | $0.81 |
| Average True Range (ATR) | 0.33 | 0.06 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 52.67 | 5.41 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.